Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

PSS54 Evaluation of treatment satisfaction with etanercept versus alternative treatments for psoriasis: a patient survery across nine European countries [Abstract]

Conway, P., Dixon, S. and Currie, Craig John 2008. PSS54 Evaluation of treatment satisfaction with etanercept versus alternative treatments for psoriasis: a patient survery across nine European countries [Abstract]. Value in Health 11 (6) , A626. 10.1111/j.1524-4733.2008.00453_2.x

Full text not available from this repository.


OBJECTIVES: Alternative treatments are available to relieve people with moderate and severe psoriasis in states of remission and relapse. The purpose of this study was characterise treatment satisfaction with alternative therapies in a survey across nine European countries. Specifically, to determine relative treatment satisfaction with etanercept. METHODS: Up to 120 subjects with moderate or severe psoriasis were identified in each of nine countries: Austria (n = 50), France (n = 120), Germany (n = 120), Italy (n = 120), The Netherlands (n = 75), Norway (n = 43), Spain (120), Sweden (n = 50) and the UK (n = 120). Patients were identified through their dermatologist, and selected in order to give a sample that represented the alternative current treatment regimens, including: biologics such as etanercept, systemic therapies, and light therapy (PUVA). Patients were excluded if they had psoriatic arthritis. Treatment severity was classified in two ways. Firstly, self-reported severity, and secondly; percent bodily coverage with psoriatic plaques. Satisfaction with treatment was defined as a response of either “satisfied” or “very satisfied” with treatment. Treatments were excluded from the analysis where <20 observations were available. Fumaderm was excluded as it was not relevant for all countries. RESULTS: There were 818 respondents in total; 45% male. Their mean age was 40.1 years (sd 11.8), and the median time since diagnosis was 12.0 years (IQR 4.0 to 21.0). The frequency of psoriasis severity for people with <3%, 3%–10%, and >10% bodily coverage was 74 (9%), 421 (52%), and 323 (39%) people, respectively. Overall, 67% of people expressed satisfaction with psoriasis treatment (64% moderate and 71% severe; p = 0.117). For people with moderate psoriasis, 3% to 10% coverage, the following percent of people reported satisfaction with treatment: cyclosporine 60% (52 of 87), PUVA 63% (54 of 86), methotrexate 65% (53 of 81) and etanercept 78% (21 of 27; p = 0.387). For people with severe psoriasis, >10% coverage, treatment satisfaction was achieved as follows: methotrexate 59% (31 of 53), PUVA 62% (28 of 45), cyclosporine 70% (19 of 27), remicade 71% (20 of 28) and etanercept 94% (46 of 49; p = 0.001). People with severe psoriasis were more satisfied with treatment with etanercept than moderate psoriasis (78% vs. 94%; p = 0.088). These findings were consistent across the nine countries. CONCLUSIONS: The majority of people with moderate and severe psoriasis expressed satisfaction with their current treatment. Treatment satisfaction with etanercept in both groups was more frequent when using etanercept (78% and 94%, respectively).

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RL Dermatology
Additional Information: ISPOR Eleventh Annual European Congress Research Poster Abstracts
Publisher: Wiley-Blackwell
ISSN: 1098-3015
Last Modified: 04 Jun 2017 03:10

Actions (repository staff only)

Edit Item Edit Item